Custom Optimer™ Affinity Reagent Development Service

Identifying relevant biomarkers from vast proteomic datasets is a major challenge in drug development. Discover how phenotype-driven discovery simplifies complexity to deliver biomarkers precisely aligned with disease context, tissue specificity, and therapeutic goals. This approach enables faster validation and supports both surface and internal targets, accelerating your path to effective, targeted therapies.

Accelerating time-to-clinic is critical for therapeutic and diagnostic success, yet traditional antibody development remains costly and slow. Optimer® binders offer a streamlined alternative, cutting timelines by up to 75%.

Discover how the Optimer® platform enables rapid binder optimization, unlocking novel targets and simplifying development, empowering researchers to reach clinical milestones faster and reduce risk across drug and diagnostic pipelines.

In this application note, using rapid in-house Optimer® selection and development processes, Optimer® reagents specific to the SARS-CoV-2 S protein were identified. The flexibility designed within the Optimer® selection process enabled analysis of the viral protein in both open and closed formats for simple assay development and monitoring and detection of live virus.

In this application note, aptamer and Optimer® reagents were selected against the antibiotic target, moxifloxacin, and incorporated into a novel electrochemical biosensor platform, for the development of rapid diagnostic assays in a point-of-care format.

Current protein-based affinity ligands are unable to resolve a range of complex protein purification problems. This poster describes several commercial case studies where Optimer® ligands are enabling solutions to these bioprocessing challenges. Download now to discover how Optimer® ligands enable new therapeutic modalities, and improved yields and cost-of-goods.

In this application note, Aptamer Group outlines its high-affinity Optimer reagents for SARS-CoV-2 S1, S2, and nucleocapsid (NC) viral target proteins which promise to improve ELISA performance compared to commercially available antibodies.

In this article, Aptamer Group discusses its collaboration with QSM Diagnostics and explains how together they have developed a fast and precise diagnostic platform for a range of diseases.

In this poster, Aptamer Group explains how high-affinity Optimers were developed and demonstrates how novel, single-reagent, gain-of-signal assay format Optimers targeting small molecules can be used for rapid, cost-effective point-of-care and field-based analytical platforms.

In this infographic, discover the benefits of fully optimized aptamers that are target specific, structurally stable and cost effective. This Optimer™ technology can be used in a range of different applications and assays including ELISA, IHC, LFD and affinity purification to enhance diagnostic and therapeutic research.

Non-exclusive OEM license grants worldwide rights for Optimer binder in molecular biology applications

Successful project delivery of Optimer binders with proven function as vaccine adjuvants

New collaboration will evaluate Aptamer’s fibrotic liver delivery vehicles with siRNA

Optimer binders will be developed for use in a cervical cancer blood test

Partnership includes initial upfront payments and will potentially deliver recurring revenues for over 10 years